Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients

NCT00635765 is registered in ClinicalTrials.gov with Ambrilia Biopharma, Inc. as lead sponsor.

NCT NCT00635765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00635765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients
Lead sponsor
Ambrilia Biopharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
June 30, 2009
Enrollment
63 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly